Larger sample sizes will clearly be needed to better characterize the spectrum of cancers associated with deleterious PALB2 mutations along with a larger sample of melanoma-only families to unambiguously determine the role of PALB2 in melanoma susceptibility. The gene discussed is PALB2; the disease is melanoma.